# Mineralys Therapeutics, Inc.: overview MLYS · Nasdaq · CIK 1933414 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mlys.md) · [Financials](/companies/mlys/financials.md) · [Filings](/companies/mlys/filings.md) · [Insiders](/companies/mlys/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.13)](/filings/0001933414-25-000142.md) | not reported | [(0.79)](/filings/0001933414-26-000084.md) | [(0.66)](/filings/0001933414-26-000114.md) | [(0.52)](/filings/0001933414-25-000142.md) | not reported | [(0.47)](/filings/0001933414-26-000084.md) | [(2.85)](/filings/0001933414-26-000114.md) | | Free cash flow | $m | [(50.2) d](/filings/0001933414-25-000142.md) | [(66.8) d](/filings/0001933414-26-000056.md) | [(45.5)](/filings/0001933414-26-000084.md) | [(30.2) d](/filings/0001933414-26-000114.md) | [(28.9) d](/filings/0001933414-25-000142.md) | [(37.9) d](/filings/0001933414-26-000056.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(5.77)](/filings/0001628280-24-012358.md) | [(1.99)](/filings/0001933414-25-000009.md) | [(3.66)](/filings/0001933414-26-000056.md) | [(2.29)](/filings/0001933414-26-000056.md) | | Free cash flow | $m | not reported | [(81.2)](/filings/0001933414-25-000009.md) | [(166)](/filings/0001933414-26-000056.md) | [(142)](/filings/0001933414-26-000056.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mlys/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Catalys Pacific, LLC](/funds/2011385.md) | 2026-06-30 | $213.2m | 7,903,838 | | Unchanged | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $207.6m | 7,692,750 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $158.8m | 5,887,038 | | Added +1,405,456 | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $158.4m | 5,871,018 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $121.7m | 4,511,689 | | Reduced −349,415 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $111.7m | 4,141,636 | | Added +1,205,696 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $106.8m | 3,958,000 | | New +3,958,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $74.4m | 2,756,770 | | Added +302,407 | | [Laurion Capital Management LP](/funds/1390202.md) | 2026-06-30 | $67.6m | 2,506,152 | | Added +274,112 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $56.9m | 2,110,300 | | Added +57,400 | ## Recent filings [All 405 filings](/companies/mlys/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 16:08 ET | [8-K](/filings/0001933414-26-000136.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001933414-26-000136 | | 2026-10-19 | 16:37 ET | [8-K](/filings/0001933414-26-000125.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001933414-26-000125 | | 2026-08-11 | 17:18 ET | [10-Q](/filings/0001933414-26-000114.md) | Quarterly report, period 2026-06-30 | 0001933414-26-000114 | | 2026-08-11 | 16:08 ET | [8-K](/filings/0001933414-26-000112.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001933414-26-000112 | | 2026-06-03 | 16:07 ET | [8-K](/filings/0001628280-26-040225.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-040225 | | 2026-06-03 | 06:02 ET | [8-K](/filings/0001628280-26-040024.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001628280-26-040024 | | 2026-05-22 | 16:50 ET | [8-K](/filings/0001933414-26-000090.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001933414-26-000090 | | 2026-05-06 | 17:15 ET | [10-Q](/filings/0001933414-26-000084.md) | Quarterly report, period 2026-03-31 | 0001933414-26-000084 | | 2026-05-06 | 16:07 ET | [8-K](/filings/0001933414-26-000082.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001933414-26-000082 | | 2026-04-08 | 08:47 ET | [DEF 14A](/filings/0001933414-26-000069.md) | Proxy statement, period 2026-05-21 | 0001933414-26-000069 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001933414-26-000056.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1933414 - Tickers: MLYS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:10 ET. No prices; not investment advice.